<http://schema.org/articleBody>
"A research team from the University of Cincinnati Cancer Institute recently developed a new oral vaccine that produces a novel immune system defense against cancer cells, particularly against the recurrence of breast cancer.<br /><br />Jason Steel, the first author of the study, and his team of UC and National Institutes of Health researchers developed the oral breast cancer vaccine from a recombinant adeno-associated virus. Unlike prior cancer vaccines developed from bacteria, AAV is a virus that has minimal negative effects on human health.<br /><br />\"AAV is special because the virus survives the stomach,\" Steel said. \"Normally, you introduce a virus by mouth and it is broken down in the stomach. This virus is resistant to breakdown, which opened up the possibility of administering it orally as a cancer vaccine.\"<br /><br />In a preclinical animal study published on January 8 in the journal Molecular Therapy, the researchers found that the AAV vaccine produced both short-term and long-term impact on the reduction of breast cancer tumors. The team said that the AAV-based vaccine could potentially serve as a human breast cancer prevention tool.<br /><br />\"We have done similar studies with different virus strains that have produced an antibody response,\" Steel said. \"With this virus, we get both an antibody and a tumor-killer T-cell response. By combining the two mechanisms of action in one vaccine, we are creating a two-pronged immune system attack on the cancer cells that appears to be more effective.\"<br /><br />Later this year, the UC team will start testing the AAV-based oral vaccine for the prevention of other cancers such as lung cancer."^^<http://www.w3.org/2001/XMLSchema#string>
<http://vaccinenewsdaily.com/stories/510533880-university-of-cincinnati-researchers-develop-oral-breast-cancer-vaccine>